Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
Relapse is the main cause of treatment failure after nonmyeloablative haploidentical transplant (haplo-HSCT). In an attempt to reduce relapse, we have developed a myeloablative (MA) haplo-HSCT approach utilizing posttransplant cyclophosphamide (PT/Cy) and peripheral blood stem cells as the stem cell...
Saved in:
| Main Authors: | Scott R. Solomon, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Asad Bashey |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2016/9736564 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation
by: Sarah Kayser, et al.
Published: (2024-12-01) -
Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis
by: Yosra M. Aljawai, et al.
Published: (2025-08-01) -
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation
by: Mustafa A. Hyder, et al.
Published: (2025-05-01) -
Haploidentical stem cell transplantation with posttransplant cyclophosphamide in children with Wiskott–Aldrich syndrome: a case report
by: Le Nguyen Ngoc Quynh, et al.
Published: (2025-02-01) -
GVHD PROPHYLAXIS WITH METHOTREXATE IN HAPLOIDENTICAL HCT USING POSTTRANSPLANT CYCLOPHOSPHAMIDE: A PHASE IB/II CLINICAL TRIAL (NCT04622956)
by: G Fatobene, et al.
Published: (2024-10-01)